Global Cord Blood Corporation (CORBF) Fair Value & Analysis
Healthcare · US · Market cap $141M
Global Cord Blood Corporation
CORBF · US
Fair value as of: Jul 15, 2026
From 24 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from $12.11 to $0.7445 (−93.9%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.2000 – $1.75 · fair‑value band $0.5579 – $0.9305 · the $0.9500 price screens above the $0.7445 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Global Cord Blood Corporation (CORBF) currently trades at $0.9500, while our model-based Fair Value estimate is $0.7445 — implying the stock looks roughly 21.6% overvalued today. We read business quality at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Global Cord Blood Corporation generated revenue of $1.2B at a net margin of 40.3%. Revenue declined 1.7% year over year. It earns a return on equity of 11.0%. The balance sheet holds a net cash position of $6.7B. Fundamentals as of Jul 15, 2026
Our scenario range runs from $0.5579 (bear case) to $0.9305 (bull case); at $0.9500, the current price sits above that range. The share trades about 46% below its 52-week high and 375% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside — at -22%, CORBF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Revenue & earnings trend
FY2018 – FY2022 · reported fiscal years
Global Cord Blood Corporation reported revenue of $1.2B in FY2022 versus $937M in FY2018, a compound +7.3%/yr. Reported net income was $501M in FY2022, compounding +20.6%/yr from FY2018.
Is CORBF fairly valued? → Check now
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | 8,423 MXN | 314.17 MXN | -96% |
| Danaher Corporation DAP | €160.60 | €75.98 | -53% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $61.97 | $14.23 | -77% |
| Agilent Technologies, Inc A | $126.49 | $63.09 | -50% |
| Waters Corporation WAT | $371.93 | $87.58 | -76% |
| Integrated Diagnostics Holdings IDHC | $0.5800 | $1.35 | +133% |
| IQVIA Holdings IQV | $183.45 | $133.46 | -27% |
| Natera, Inc NTRA | $228.80 | $24.55 | -89% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Global Cord Blood Corporation (CORBF) undervalued?
What is the fair value of CORBF?
What is the quality score of CORBF?
What is the revenue of Global Cord Blood Corporation (CORBF)?
What is the net profit margin of CORBF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Global Cord Blood Corporation analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.